<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937725</url>
  </required_header>
  <id_info>
    <org_study_id>PI21-2247 TFM</org_study_id>
    <nct_id>NCT04937725</nct_id>
  </id_info>
  <brief_title>Reading Problems Associated With Central Nervous System (CNS) Pathologies.</brief_title>
  <official_title>Reading Problems Associated With Central Nervous System Pathologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clínico Universitario de Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Río Hortega</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to analyse eye movements, their alterations and influence in reading&#xD;
      performance in patients with acquired CNS diseases and compare them with people of the same&#xD;
      age, without neurological or ocular pathology and with normal reading speed and pattern.&#xD;
&#xD;
      The exploration is focused on the oculomotor system in patients with CNS diseases, even&#xD;
      without involvement of the primary visual pathway, and reveals more involvement than the one&#xD;
      obtained by a simple ophthalmological examination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following protocol will be applied:&#xD;
&#xD;
      Neuropsychological function Clock Test- Clock Drawing, whose score corresponds to a scale of&#xD;
      1 to 6, from perfect organization to severe disorder respectively, with a cognitive deficit&#xD;
      being a result greater than 3. This test is used to detect signs of heminegligence in&#xD;
      addition to the Line Bisection Test. It will consider the displacement of the central mark to&#xD;
      the right side as a positive sign.&#xD;
&#xD;
      Mini-Cognitive Exam, whose cut-off score corresponds to 23 out of the 30 total, equal to or&#xD;
      less than this figure, would indicate the presence of a cognitive deficit.&#xD;
&#xD;
      Far and near Best corrected visual acuity Primary gaze position Cover test (far and near)&#xD;
      Extrinsic ocular motility Nystagmus presence Intrinsic ocular motility Biomicroscopy of the&#xD;
      anterior pole Computerized visual field 30-2 Intraocular pressure Ocular fundus examination&#xD;
      Records with Tobii Pro Nano Hardware Package eye-tracking system and Tobii Pro Lab - Full&#xD;
      Edition software.&#xD;
&#xD;
      Reading performance assessment: International Reading Speed Texts (IReST) Attentional&#xD;
      questionnaire based on the IReST, two simple answer questions (one word) will be formulated&#xD;
      for each text, at the end of the reading to check the reading comprehension of the patient&#xD;
      Evaluation of the speed and quality of horizontal and vertical reading: Test DEM&#xD;
      (Developmental Eye Movement).&#xD;
&#xD;
      Eye-tracking test: with an animation of a moving circle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reading performance</measure>
    <time_frame>24 Hours</time_frame>
    <description>International Reading Speed Texts (IReST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reading performance</measure>
    <time_frame>24 Hours</time_frame>
    <description>DEM (Developmental Eye Movement).ocular (DEM)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Eye tracking</measure>
    <time_frame>24 Hours</time_frame>
    <description>Eye-tracking test</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Injury Brain</condition>
  <condition>Eye Abnormalities</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Parkinson Disease</condition>
  <condition>Ataxia, Cerebellar</condition>
  <arm_group>
    <arm_group_label>Patients without neurological pathologies</arm_group_label>
    <description>Patients with no history of neurological diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>eye tracking</intervention_name>
    <description>Eye tracker will be used to evaluate study parameters</description>
    <arm_group_label>Patients without neurological pathologies</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Normal population (no pathology) and people with neurological pathologies such as multiple&#xD;
        sclerosis, Parkinson, tumours, or stroke, cerebellum ataxia and other miscellaneous&#xD;
        neurological disorders.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients and normal volunteers with ages between 18 and 80 years old.&#xD;
&#xD;
          -  Clinical radiological neurological stability in acute CNS diseases (≥ 3 months after&#xD;
             ACD).&#xD;
&#xD;
          -  Best distant binocular visual acuity, equal or greater than 0.5 (Decimal Scale). Best&#xD;
             close binocular visual acuity, equal or greater than 20/40.Glasses or soft contact&#xD;
             lenses users.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of visual heminegligence evaluated with clock drawing test and line bisection&#xD;
             test.&#xD;
&#xD;
          -  Presence of visual agnosia: Poppelreuter-Ghent © test.&#xD;
&#xD;
          -  Presence of cognitive deficit: mini mental state examination (MMSE), with sufficient&#xD;
             residual hearing capacity.&#xD;
&#xD;
          -  Medical history, or presence after ophthalmic examination of: maculopathy, advanced&#xD;
             cataracts, ophthalmological diseases affecting central visual acuity or macular&#xD;
             fixation.&#xD;
&#xD;
          -  Healthy control subjects should have normal monocular perimetry using standard Swedish&#xD;
             interactive threshold algorithm (SITA) Central 30-2 Humphrey® Perimeter Test .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IOBA - Universidad de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eye tracking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Eye Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

